Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis.
The newest generation of fluoroquinolones have proven efficacy against bacterial organisms associated with acute exacerbation of chronic bronchitis (AECB). Gemifloxacin, as one of the quinolones in this class, exhibits many of the pharmacokinetic and pharmacodynamic characteristics of the class with a few notable differences. Against Streptococccus pneumoniae it has a lower minimal inhibitory concentration (MIC) than the other respiratory fluoroquinolones and it has activity against both bacterial DNA gyrase and topoisomerase IV. The increased activity of gemifloxacin against both enzymes may be associated with decreased rates of resistance. Clinically, gemifloxacin has been shown to have positive effects on length of hospitalization and increased success at long-term follow-up in AECB patients. These associations were observed in noninferiority comparison studies. Although an advantage with the use of gemifloxacin in AECB is suggested, there are no comparison data is available to conclude that gemifloxacin is superior to the other respiratory fluoroquinolones. Gemifloxacin is generally well tolerated, but is associated with a characteristic rash and gastrointestinal upset as its most common observed side effects.
Jivcu
Cristian
C
Department of Internal Medicine, Banner Good Samaritan Medical Center, Phoenix, AZ, USA. cjivcu@gmail.com
Gotfried
Mark
M
D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D029481:Bronchitis, Chronic / Q000188:drug therapy* / Q000191:economics / Q000382:microbiology; D003362:Cost-Benefit Analysis; D004195:Disease Models, Animal; D016527:Drug Costs; D024881:Drug Resistance, Bacterial; D024841:Fluoroquinolones / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000077735:Gemifloxacin; D006801:Humans; D008826:Microbial Sensitivity Tests; D009287:Naphthyridines / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D000077735:Gemifloxacin
Chest. 2002 May;121(5 Suppl):136S-141S
12010842
J Chemother. 2000 Aug;12(4):314-25
10949981
Diagn Microbiol Infect Dis. 2005 Jan;51(1):45-9
15629228
Antimicrob Agents Chemother. 2007 Apr;51(4):1315-20
17296740
Curr Med Res Opin. 2007 Jan;23(1):1-7
17261234
Am J Health Syst Pharm. 2002 Jul 15;59(14):1357-65
12132563
Antimicrob Agents Chemother. 2000 Feb;44(2):304-10
10639354
East Mediterr Health J. 2005 Jan-Mar;11(1-2):36-44
16532669
Postgrad Med. 2001 Feb;109(2):39-47
11272693
Am J Manag Care. 2004 Oct;10(10):689-96
15521160
Antimicrob Agents Chemother. 1997 Dec;41(12):2733-7
9420048
J Antimicrob Chemother. 2000 Apr;45 Suppl 1:1-12
10824026
Clin Ther. 2002 Apr;24(4):639-52
12017408
Int J Antimicrob Agents. 2001 Jul;18(1):19-27
11463522
Monaldi Arch Chest Dis. 1994 Apr;49(2):159-64
8049702
Control Clin Trials. 1996 Feb;17(1):1-12
8721797
J Antimicrob Chemother. 2000 Mar;45:9-17
10719007
J Chemother. 2006 Aug;18(4):373-8
17024792
J Chemother. 2006 Dec;18(6):634-40
17267342
Pharmacotherapy. 2001 Dec;21(12):1468-72
11765299
Ann Intern Med. 1987 Feb;106(2):196-204
3492164
J Antimicrob Chemother. 2000 Apr;45 Suppl 1:79-85
10824037
Respir Med. 2003 Mar;97(3):242-9
12645831
Pharmacotherapy. 2002 Feb;22(2):160-5
11837554
Infect Dis Clin North Am. 2004 Dec;18(4):861-82, ix
15555829
Clin Infect Dis. 2005 Dec 15;41(12):1697-705
16288390
Drugs. 2004;64(10):1091-124
15139788
Chest. 2007 Jan;131(1):1-2
17218546
Antimicrob Agents Chemother. 1998 Mar;42(3):521-7
9517926
J Chemother. 2001 Jun;13(3):288-98
11450888
J Antimicrob Chemother. 1999 Mar;43 Suppl A:97-105
10225579
Am J Respir Crit Care Med. 1995 Nov;152(5 Pt 2):S77-121
7582322
Antimicrob Agents Chemother. 2000 Mar;44(3):633-9
10681330
Int J Antimicrob Agents. 2007 Apr;29(4):374-9
17241772
Am Rev Respir Dis. 1992 Oct;146(4):1067-83
1416398
Treat Respir Med. 2006;5(6):437-65
17154673
Respir Med. 2004 Aug;98(8):697-707
15303633
Chest. 2000 May;117(5 Suppl 2):380S-5S
10843981
Clin Infect Dis. 2001 Sep 15;33 Suppl 3:S187-92
11524718
Am J Med. 2005 Jul;118 Suppl 7A:39S-44S
15993676
Med Clin North Am. 2001 Nov;85(6):1493-509
11680113
Ann Pharmacother. 2004 Jul-Aug;38(7-8):1226-35
15187209
Drugs. 2002;62(1):13-59
11790155
Antimicrob Agents Chemother. 2004 Aug;48(8):3165-8
15273141
Can Respir J. 2003 Jul-Aug;10(5):248-58
12945001
J Antimicrob Chemother. 2002 Jun;49(6):893-5
12039880
Clin Infect Dis. 2006 Jan 1;42(1):73-81
16323095
Int J Antimicrob Agents. 2004 Jun;23(6):533-46
15194123
Clin Microbiol Infect. 2005 Dec;11(12):1040-4
16307562